Speak directly to the analyst to clarify any post sales queries you may have.
Global Oligonucleotide Therapeutics Market 2020-2024
The oligonucleotide therapeutics market, and it is poised to grow by USD 901.18 mn during 2020-2024, progressing at a CAGR of 10% during the forecast period. The reports on oligonucleotide therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of cancer and the need for personalized medicines for neurodegenerative disorders.
The oligonucleotide therapeutics market analysis includes segments as application, technology, and geographic landscape.
The oligonucleotide therapeutics market is segmented as below:
By Application
- Neurological disorders
- Cancer
- Others
By Technology
- Antisense/RNAi oligonucleotides
- Others
By Geographic Landscapes
- North America
- Europe
- APAC
- South America
- MEA
This study identifies the increased availability of approved drugs as one of the prime reason driving the oligonucleotide therapeutics market growth during the next few years.
The research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of critical parameters. The oligonucleotide therapeutics market covers the following areas:
- Oligonucleotide therapeutics market sizing
- Oligonucleotide therapeutics market forecast
- Oligonucleotide therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position. In line with this, this report provides a detailed analysis of several leading oligonucleotide therapeutics market vendors that include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holding ASA, and Sarepta Therapeutics Inc. Also, the oligonucleotide therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of critical parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. This market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
Executive Summary
The research team recognizes the following companies as the key players in the global oligonucleotide therapeutics market: Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holding ASA, and Sarepta Therapeutics Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increased availability of approved drugs."
According to the report, one of the major drivers for this market is the increasing incidence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Biogen Inc.
- Dynavax Technologies Corp.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Miragen Therapeutics Inc.
- PCI Biotech Holding ASA
- Sarepta Therapeutics Inc.
